Friday-Sunday, March 2-4, 2018 — Miami, Florida

The 15th Annual Winter Lung Cancer Conference

March 2-4, 2018

Turnberry Isle Miami
19999 West Country Club Drive
Miami, FL 33180
Hotel Phone: (305) 932-6200

Meeting Room:
Grand Ballroom (Lobby Level)
Note from Moderators:
This coming March will mark the 15th year of the Winter Lung Cancer Conference, and like a fine wine, the event continues to get better with age. Designed to provide thorough, practically oriented reviews of key management issues in this all too prevalent disease, this engaging, one-of-a-kind offering will once again span parts of 3 days and feature a stellar multidisciplinary faculty panel and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. To augment the conference’s interactivity, each clinician will be provided with a specially configured iPad® to use throughout the program to participate in audience polling, view all the presentation slides and anonymously submit questions to the panelists for the aforementioned Q&A. The conference’s educational design and the topics that will be discussed offer interested clinicians the opportunity to access the in-depth perspectives of some of the top minds in the field regarding significant new data sets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with this challenging disease.

So as you begin to make your plans for 2018, we hope you will join us in sunny South Florida for a lung cancer learning experience unlike any other out there.

Co-Chairs and Moderators
Rogerio C Lilenbaum, MD
Professor of Medicine
Yale School of Medicine
Chief Medical Officer
Smilow Cancer Hospital
Yale Cancer Center
New Haven, Connecticut

Mark A Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
Orlando, Florida

Neil Love, MD
Research To Practice
Miami, Florida

Ethan M Basch, MD, MSc (Keynote)
Professor of Medicine and Public Health
Director, Cancer Outcomes Research Program
Co-Leader, Cancer Prevention and Control
Associate Chief, Division of Oncology
University of North Carolina
Chapel Hill, North Carolina

Jeffrey Crawford, MD
George Barth Geller
Professor for Research in Cancer
Co-Director, Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, North Carolina

Jesse R Fann, MD, MPH
Director, Psychiatry and Psychology Service
Seattle Cancer Care Alliance
Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor, Department of Psychiatry and Behavioral Sciences
University of Washington
Seattle, Washington

Leena Gandhi, MD, PhD
Director, Perlmutter Cancer Center
Langone Health
New York University
New York, New York

Edward B Garon, MD, MS
Associate Professor
Director, Thoracic Oncology Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

David E Gerber, MD
Associate Professor
Division of Hematology-Oncology
Associate Director for Clinical Research
Co-Leader, Experimental Therapeutics Program
Co-Director, Lung Disease Oriented Team
Harold C Simmons Comprehensive Cancer Center
University of Texas
Southwestern Medical Center
Dallas, Texas

Scott N Gettinger, MD
Associate Professor of Medicine, Medical Oncology
Yale School of Medicine
Thoracic Oncology Program Developmental Therapeutics
Smilow Cancer Hospital
New Haven, Connecticut

Jennifer M Kapo, MD
Associate Professor of Medicine (Geriatrics)
Chief, Palliative Medicine
Smilow Cancer Hospital
Yale Cancer Center
New Haven, Connecticut

Billy W Loo Jr, MD, PhD, DABR
Associate Professor, Thoracic Radiation Oncology Program Leader
New Technologies Committee Co-Chair
Department of Radiation Oncology
Stanford Cancer Institute
Stanford, California

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Anne S Tsao, MD
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Douglas E Wood, MD
The Henry N Harkins Professor and Chair
Department of Surgery
University of Washington
Seattle, Washington

Additional faculty will be announced in the coming weeks.

Full agenda and speaker information will be made available by later this year. Times and schedule are subject to change.

Preliminary Agenda

Friday, March 2nd
6:30 PM – 7:15 PM Welcome Reception
7:15 PM – 7:45 PM Keynote Lecture
7:45 PM – 8:00 PM Q&A Session

Saturday, March 3rd
7:00 AM – 8:00 AM Breakfast
8:00 AM – 12:30 PM Morning General Session
12:30 PM – 1:30 PM Lunch
1:30 PM – 3:30 PM Afternoon General Session

Sunday, March 4th
7:00 AM – 8:00 AM Breakfast
8:00 AM – 12:00 PM General Session
12:00 PM Meeting adjourns

Keynote Lecture: Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

Current and Future Application of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

  • Emerging role of anti-PD-1/PD-L1 antibodies in patients with locally advanced disease
  • PD-L1 and other potential predictors of response to immune checkpoint inhibition in NSCLC
  • Available research information with the use of anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy in patients with previously untreated metastatic NSCLC and implications for clinical care
  • Ongoing evaluation of novel immunotherapeutic approaches, including combination strategies

EGFR Tumor Mutations

  • Molecular testing in clinical practice: Role of multiplex testing/next-generation sequencing and rapid plasma genotyping
  • Selection of first-line systemic therapy for patients with EGFR-positive disease
  • Available efficacy and safety data with and practical integration of osimertinib; emerging role in the first-line setting
  • Other resistance mutations beyond T790M; management of disease progressing on osimertinib

ALK, ROS1, BRAF and Other Potentially Targetable Mutations

  • Selection of first-line therapy for patients with ALK- or ROS1-rearranged NSCLC
  • Approved and investigational tyrosine kinase inhibitors (TKIs) for patients with ALK-positive disease that progresses on first-line TKI therapy
  • Identification of and treatment for patients with BRAF V600E mutations
  • Potential therapeutic opportunities associated with the identification of HER2 mutations/amplifications, RET rearrangements, MET mutations/amplification and NTRK gene fusions

Management of NSCLC with No Identified Targetable Mutations; Protocol and Nonprotocol Treatment of Mesothelioma and Small Cell Lung Cancer

  • Sequencing of systemic therapies and clinical trial options for patients with metastatic squamous cell carcinoma
  • Sequencing of systemic therapies and clinical trial options for patients with metastatic nonsquamous cell lung cancer
  • Emerging role of immune checkpoint inhibitors in malignant pleural mesothelioma
  • Current management and ongoing clinical trials in small cell lung cancer

Lung Cancer Interdisciplinary Tumor Board

  • Prognostic molecular models in early-stage lung cancer
  • Radiation therapy: Challenging clinical scenarios and related management issues
  • Adjuvant treatment decision-making
  • The surgical management of lung cancer
  • Recent therapeutic advances and novel trial concepts for patients with locally advanced NSCLC

Practical Challenges in the Use of Immunotherapy

  • Clinical complications associated with immunotherapy; immunotherapy in patients with a history of autoimmune disease
  • Management approach for patients with prolonged response to an anti-PD-1/PD-L1 antibody: Is there a role for stopping therapy?
  • Immunotherapy in elderly patients and those with significant comorbidities
  • Current role of anti-PD-1/PD-L1 antibodies in patients with EGFR, ALK or other targetable mutations

Target Audience:
This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Design evidence-based strategies for the diagnosis and management of Stage I to Stage III non-small cell lung cancer (NSCLC), considering the potential contributions of systemic and/or local therapeutic modalities.
  • Evaluate existing guideline recommendations regarding the indications and optimal testing platform for mutational analysis in patients with metastatic NSCLC, and utilize this information to implement a comprehensive approach to genomic assessment.
  • Recognize available and emerging research information validating the utility of diagnostic assays designed to measure EGFR, ALK, ROS1, BRAF and PD-L1 status, assess which testing platform(s) should be utilized, and appropriately employ the results of these assessments to individualize first- and later-line therapy for patients with NSCLC based on their potential response (or lack thereof) to a specific treatment.
  • Review published research data documenting the safety and efficacy of anti-PD-1 antibodies used as monotherapy or in combination with chemotherapy for patients with newly diagnosed metastatic NSCLC.
  • Consider age, performance status, PD-L1 tumor proportion score and other patient- or disease-related factors to guide the selection of induction and maintenance systemic therapy for patients with metastatic NSCLC without an identifiable driver mutation.
  • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the long-term management of EGFR mutation-positive NSCLC.
  • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
  • Assess new oncogenic pathways mediating the growth of unique tumor subsets, and recall emerging data with experimental agents exploiting these targets.
  • Describe ongoing trials evaluating novel applications of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, anti-PD-1/PD-L1 antibodies in combination with other checkpoint inhibitors, chemotherapy or targeted therapy) for patients with diverse lung cancer variants, and counsel appropriately selected individuals about potential participation.
  • Formulate management strategies for small cell lung cancer, considering the contributory roles of local and systemic therapy in addition to current research studies evaluating novel immunotherapeutic and targeted approaches.
  • Consider the use of multimodality therapy for appropriate patients with mesothelioma who may potentially be cured with this approach, and devise optimal management strategies for those with advanced disease, including the option of clinical trial participation.

Accreditation Statements:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CME Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Credit Form:
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Designation Statement:
This educational activity for 10.1 contact hours is provided by Research To Practice.

This activity is awarded 10.1 ANCC pharmacotherapeutic contact hours.

CNE Credit Form:
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

ONCC/ILNA Certification Information:
This program will be submitted for ONCC/ILNA certification.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Lilly, Novartis and Takeda Oncology.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Turnberry Isle Miami
19999 West Country Club Drive
Aventura, FL 33180
Hotel Phone: (305) 932-6200

Meeting Room:
Grand Ballroom (Lobby Level)

Room Reservations:
A special discounted room rate of $299 (plus applicable tax & discounted resort fee of $10) is available to conference attendees at the Turnberry Isle Miami hotel. To secure accommodations, please contact the Turnberry Isle Miami directly at (888) 539-7894 or (305) 932-6200. A personal credit card will be required to secure accommodations.

Please mention you are participating in the Winter Lung Cancer Conference to receive the special group rate.

Room reservations must be made by Friday, February 9, 2018. A limited number of rooms are available, and we encourage you to make your reservations early. After January 30, 2018, the hotel will offer the best rates based on room availability.

View Larger Map

Driving Directions:

From Miami International Airport

  • The drive from Miami International Airport takes approximately 35 minutes.
  • Exit the airport and follow the signs to I-95 North.
  • Take I-95 North to Ives Dairy Road, exit 16 (also called NE 203 Street).
  • Go East on Ives Dairy Road to US1 (also called Biscayne Blvd).
  • Turn right on Biscayne Blvd and immediately make first left at the traffic light onto Aventura Blvd (NE 199 Street).
  • Continue to the end and turn right on West Country Club Drive. The resort's main entrance is on your left.

(Please note: There is a $1.25 toll on expressway 112.)

From Fort Lauderdale International Airport

  • The drive from the Fort Lauderdale International Airport takes approximately 20 minutes.
  • Exit the airport and follow signs to I-95 South.
  • Take I-95 South to Ives Dairy Road, exit 16 (also called NE 203 Street).
  • Go East on Ives Dairy Road to US1 (also called Biscayne Blvd).
  • Turn right on Biscayne Blvd and immediately make the first left at the traffic light onto Aventura Blvd (NE 199 Street).
  • Continue to the end and turn right on West Country Club Drive. The resort's main entrance is on your left.

This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.

Registration Fees:
This event is free of charge for practicing physicians, fellows, nurses and other healthcare providers involved in the treatment of lung cancer.

For all other individuals, including industry professionals*, a registration fee of $1,075 is available through February 1, 2018 and then $1,175 after this day. All fees processed will be nonrefundable after January 30, 2018 (5:00 PM Eastern Time). To cancel your registration, please contact our Meeting Services department at or (800) 233-6153.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/ industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.